Thelansis

Alpha-Mannosidosis Market Outlook Thelansis’s “Alpha-Mannosidosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Alpha-Mannosidosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What in...

Alpha-Mannosidosis Market Outlook Thelansis’s “Alpha-Mannosidosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Alpha-Mannosidosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Alpha-Mannosidosis Overview Alpha-mannosidosis is an autosomal recessive lysosomal storage disease caused by MAN2B1 gene mutations. It is diagnosed by detecting low levels of acidic alpha-mannosidase enzyme activity in peripheral blood leukocytes or cultured skin fibroblasts, with affected individuals displaying 5–15% of regular leukocyte activity. In most patients, the disease is clinically recognised in the first decade of life, progression is slo...

  Alpha-mannosidosis is an autosomal recessive lysosomal storage disease caused by MAN2B1 gene mutations. It is diagnosed by detecting low levels of acidic alpha-mannosidase enzyme activity in peripheral blood leukocytes or cultured skin fibroblasts, with affected individuals displaying 5–15% of regular leukocyte activity. In most patients, the disease is clinically recognised in the first decade of life, progression is slow, and ataxia develops between 20 to 30 years. Long-term enzyme replacement therapy (ERT) is a treatment option for alpha-mannosidosis, and the first human recombinant form of alpha-mannosidase available for ERT is velmanase alfa. Patients with alpha-mannosidosis who were treated with velmanase alfa improved in biomarkers, motor function, pulmonary function, immunologic profile, and quality of life in clinical trials. Intracellular accumulation of mannose-rich oligosaccharides causes various clinical symptoms, including hearing loss, intellectual disabilities, an...